Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2018-11-09 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2018
Director's Dealing
2018-11-09 English
10-Q 3Q 2018
Interim / Quarterly Report Q3 2018
2018-10-31 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 23, 2018, reporting a significant corporate event: Johnson & Johnson's agreement to launch a tender offer to acquire all outstanding shares of Ci:z Holdings Co., Ltd. The text details the terms of the tender offer, the strategic background, and the expected timeline for the transaction. It also references a press release attached as an exhibit. The content focuses on a merger and acquisition activity, specifically a tender offer, which aligns with the M&A Activity category. The document is not a full annual or quarterly report, nor is it a simple announcement of a report publication. It contains substantive information about the transaction itself. Therefore, the appropriate classification is M&A Activity (TAR).
2018-10-23 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 16, 2018, reporting Johnson & Johnson's third quarter 2018 financial results and an intangible asset impairment charge. It includes a press release and unaudited supplementary sales data for the quarter ended September 30, 2018. The 8-K form is used for current reports to announce material events and financial results outside of the annual or quarterly reports. The content focuses on earnings and financial condition updates for a quarter, consistent with an Earnings Release. The document is about 4498 characters, which is typical for an 8-K earnings announcement. Therefore, the filing type is Earnings Release (ER).
2018-10-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically describes the completion of a divestiture transaction (sale of LifeScan business) and references a press release attached as an exhibit. There are no financial statements or detailed financial data included, only a description of the event and a reference to a press release. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. The document length is short (2951 characters), and it is not a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-02 English
Director's Dealing 2018
Director's Dealing
2018-09-17 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.